Scott M Dehm

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. pmc mRNA splicing variants: exploiting modularity to outwit cancer therapy
    Scott M Dehm
    Department of Laboratory Medicine and Pathology, Masonic Cancer Center, University of Minnesota Twin Cities, Minneapolis, MN 55455, USA
    Cancer Res 73:5309-14. 2013
  2. pmc Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance
    Scott M Dehm
    Department of Urology and Biochemistry, Mayo Clinical College of Medicine, Rochester, Minnesota, USA
    Cancer Res 68:5469-77. 2008
  3. pmc Alternatively spliced androgen receptor variants
    Scott M Dehm
    Department of Laboratory Medicine and Pathology, Masonic Cancer Center, University of Minnesota, Mayo Mail Code 806, 420 Delaware Street SE, Minneapolis, Minnesota 55455, USA
    Endocr Relat Cancer 18:R183-96. 2011
  4. pmc TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer
    Michael D Nyquist
    Masonic Cancer Center, Graduate Program in Molecular, Cellular, and Developmental Biology and Genetics, and Biostatistics and Bioinformatics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455
    Proc Natl Acad Sci U S A 110:17492-7. 2013
  5. ncbi request reprint Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer
    Hannelore V Heemers
    Department of Urology Research Biochemistry, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Res 67:10592-9. 2007
  6. ncbi request reprint p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6
    Jose D Debes
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer Res 65:5965-73. 2005
  7. pmc Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosis
    Kristin A Raclaw
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Prostate 68:1696-706. 2008
  8. ncbi request reprint Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells
    Scott M Dehm
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Biol Chem 281:27882-93. 2006
  9. pmc Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines
    Yingming Li
    Masonic Cancer Center, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Cancer Res 73:483-9. 2013
  10. ncbi request reprint Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells
    Scott M Dehm
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer Res 67:10067-77. 2007

Collaborators

Detail Information

Publications21

  1. pmc mRNA splicing variants: exploiting modularity to outwit cancer therapy
    Scott M Dehm
    Department of Laboratory Medicine and Pathology, Masonic Cancer Center, University of Minnesota Twin Cities, Minneapolis, MN 55455, USA
    Cancer Res 73:5309-14. 2013
    ..In this review, the role of splice variants in cancer therapy resistance will be discussed, with examples of how mechanistic understanding of these processes has led to the development of novel strategies for therapy resensitization...
  2. pmc Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance
    Scott M Dehm
    Department of Urology and Biochemistry, Mayo Clinical College of Medicine, Rochester, Minnesota, USA
    Cancer Res 68:5469-77. 2008
    ..Together, our data describe a simple and effective mechanism by which PCa cells can synthesize a constitutively active AR and thus circumvent androgen ablation...
  3. pmc Alternatively spliced androgen receptor variants
    Scott M Dehm
    Department of Laboratory Medicine and Pathology, Masonic Cancer Center, University of Minnesota, Mayo Mail Code 806, 420 Delaware Street SE, Minneapolis, Minnesota 55455, USA
    Endocr Relat Cancer 18:R183-96. 2011
    ..In this review, we will summarize the various alternatively spliced AR variants that have been discovered, with a focus on their role and origin in the pathologic conditions of AIS and PCa...
  4. pmc TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer
    Michael D Nyquist
    Masonic Cancer Center, Graduate Program in Molecular, Cellular, and Developmental Biology and Genetics, and Biostatistics and Bioinformatics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455
    Proc Natl Acad Sci U S A 110:17492-7. 2013
    ..These findings demonstrate that AR gene rearrangements are a unique resistance mechanism by which AR transcriptional activity can be uncoupled from endocrine regulation in CRPC. ..
  5. ncbi request reprint Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer
    Hannelore V Heemers
    Department of Urology Research Biochemistry, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Res 67:10592-9. 2007
    ..These results suggest a novel indirect mechanism of androgen action on FHL2 expression and provide evidence that SRF is an important determinant of AR action in prostate cancer cells...
  6. ncbi request reprint p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6
    Jose D Debes
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer Res 65:5965-73. 2005
    ....
  7. pmc Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosis
    Kristin A Raclaw
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Prostate 68:1696-706. 2008
    ..In the current study, we examined the androgenic regulation of FLIP and its contribution to protecting prostate cancer cells from death receptor-mediated apoptosis...
  8. ncbi request reprint Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells
    Scott M Dehm
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Biol Chem 281:27882-93. 2006
    ..Our data thus demonstrate that the AR can inappropriately activate transcription in ADI PCa cells via mechanisms that are resistant to castration and AR antagonism, the two modes of androgen ablation used to treat advanced PCa...
  9. pmc Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines
    Yingming Li
    Masonic Cancer Center, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Cancer Res 73:483-9. 2013
    ....
  10. ncbi request reprint Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells
    Scott M Dehm
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer Res 67:10067-77. 2007
    ..These data show that ligand-dependent and ligand-independent AR activation rely on fundamentally distinct mechanisms, and define WxxLF as the major transactivation motif within the AR TAU5 domain...
  11. ncbi request reprint Molecular regulation of androgen action in prostate cancer
    Scott M Dehm
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Cell Biochem 99:333-44. 2006
    ..We will also summarize several recent studies that have attempted to unravel how these genes are deregulated in androgen depletion independent prostate cancer...
  12. ncbi request reprint Androgen receptor gene rearrangements: new perspectives on prostate cancer progression
    Lucas J Brand
    Graduate Program in Microbiology, Immunology, and Cancer Biology, University of Minnesota, Minneapolis, MN 55455, USA
    Curr Drug Targets 14:441-9. 2013
    ..We further suggest that genomic events leading to ARV expression could act as novel biomarkers of disease progression that may guide the optimal use of current and next-generation AR-targeted therapy...
  13. pmc Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal
    Siu Chiu Chan
    Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Biol Chem 287:19736-49. 2012
    ..Together, our data demonstrate that diverse truncated AR species with varying efficiencies of nuclear localization can contribute to castration-resistant PCa pathology by driving persistent ligand-independent AR transcriptional activity...
  14. doi request reprint FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants
    Laura R Bohrer
    Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
    Prostate 73:1017-27. 2013
    ..FOXO1, a key downstream effector of PTEN, inhibits androgen-independent activation of the AR. However, the underlying mechanism remains elusive...
  15. ncbi request reprint Androgen receptor structural and functional elements: role and regulation in prostate cancer
    Scott M Dehm
    Departments of Urology and Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, Minnesota 55905, USA
    Mol Endocrinol 21:2855-63. 2007
    ..A comprehensive understanding of the role and functional relationships between these AR domains could lead to the development of novel AR-directed therapies for prostate cancer...
  16. ncbi request reprint Regulation of androgen receptor signaling in prostate cancer
    Scott M Dehm
    Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, USA
    Expert Rev Anticancer Ther 5:63-74. 2005
    ..How these mechanisms of androgen receptor activation could be targeted in this advanced stage of the disease is also discussed...
  17. pmc Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression
    Yingming Li
    Department of Electrical and Computer Engineering, Masonic Cancer Center, University of Minnesota, Twin Cities, Minnesota 55455, USA
    Cancer Res 71:2108-17. 2011
    ..Together, these data provide the first report of AR intragenic rearrangements in CRPCa and an association with pathologic expression of truncated AR isoforms in a cell-based model of PCa progression...
  18. doi request reprint Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression
    Michael D Nyquist
    Masonic Cancer Center, University of Minnesota, Twin Cities, Minneapolis, MN 55455, USA
    Horm Cancer 4:61-9. 2013
    ..In this review, we will highlight genomic alterations that are important for development and progression of PCa, with a focus on how these alterations affect, and are affected by, activity of the AR signaling axis...
  19. ncbi request reprint The modification of Sp3 isoforms by SUMOylation has differential effects on the SRC1A promoter
    Danielle J P Ellis
    Cancer Research Unit, Health Research Division, Saskatchewan Cancer Agency, Saskatoon, SK, Canada
    Gene 379:68-78. 2006
    ..These results provide new insights into the complexity of Sp3 mediated transcription which appears to be highly dependent on the isoform bound, SUMOylation status and the promoter context...
  20. ncbi request reprint Regulation of alternative SRC promoter usage in HepG2 hepatocellular carcinoma cells
    Scott M Dehm
    Cancer Research Unit, Health Research Division, Saskatchewan Cancer Agency, Saskatoon, Canada
    Gene 337:141-50. 2004
    ..This approach identified a HepG2-specific DH site that displayed activating potential towards the SRC1alpha promoter. These results thus provide important insight to the mechanism of SRC transcriptional activation in liver cancer cells...
  21. pmc SRC proximal and core promoter elements dictate TAF1 dependence and transcriptional repression by histone deacetylase inhibitors
    Scott M Dehm
    Department of Biochemistry, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5E5, Canada
    Mol Cell Biol 24:2296-307. 2004
    ....